Technical Analysis for NTRA - Natera, Inc.

Grade Last Price % Change Price Change
B 106.53 -3.26% -3.59
NTRA closed down 3.26 percent on Friday, May 31, 2024, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week Closing High Bullish -3.26%
NR7 Range Contraction -3.26%
Narrow Range Bar Range Contraction -3.26%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Natera, Inc. Description

Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Acid IBD 50 Medical Genetics Medical Test In Vitro Lab Testing Applied Genetics Genetic Diseases DNA Genetic Testing In Vitro Fertilization DNA Paternity Testing Prenatal Testing Severe Genetic Diseases

Is NTRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 110.74
52 Week Low 36.9
Average Volume 1,190,346
200-Day Moving Average 68.71
50-Day Moving Average 97.25
20-Day Moving Average 104.76
10-Day Moving Average 108.26
Average True Range 3.26
RSI (14) 59.18
ADX 31.9
+DI 24.62
-DI 19.65
Chandelier Exit (Long, 3 ATRs) 100.96
Chandelier Exit (Short, 3 ATRs) 101.79
Upper Bollinger Bands 114.84
Lower Bollinger Band 94.67
Percent B (%b) 0.59
BandWidth 19.26
MACD Line 3.94
MACD Signal Line 4.10
MACD Histogram -0.1611
Fundamentals Value
Market Cap 12.8 Billion
Num Shares 120 Million
EPS -4.51
Price-to-Earnings (P/E) Ratio -23.62
Price-to-Sales 8.55
Price-to-Book 10.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 114.74
Resistance 3 (R3) 115.23 112.98 113.37
Resistance 2 (R2) 112.98 110.89 112.74 112.91
Resistance 1 (R1) 109.76 109.60 108.64 109.27 112.46
Pivot Point 107.51 107.51 106.95 107.27 107.51
Support 1 (S1) 104.29 105.42 103.17 103.80 100.60
Support 2 (S2) 102.04 104.13 101.80 100.15
Support 3 (S3) 98.82 102.04 99.69
Support 4 (S4) 98.33